{
    "Trade/Device Name(s)": [
        "PLAC\u00ae Test for Lp-PLA2 Activity",
        "Lp-PLA2 Activity Test Calibrators",
        "Lp-PLA2 Activity Test Controls"
    ],
    "Submitter Information": "diaDexus, Inc.",
    "510(k) Number": "K141575",
    "Predicate Device Reference 510(k) Number(s)": [
        "K030477"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NOE",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "October 30, 2014",
    "Summary Letter Received Date": "November 3, 2014",
    "Submission Date": "December 05, 2014",
    "Regulation Number(s)": [
        "21 CFR 866.5600",
        "21 CFR 862.1150",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Low-density lipoprotein immunological test system",
        "Calibrators, Secondary",
        "Quality Control Material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "immunology"
    ],
    "Analyte(s)": [
        "Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)"
    ],
    "Specimen Type(s)": [
        "EDTA-plasma",
        "Serum"
    ],
    "Specimen Container(s)": [
        "K2 EDTA tube",
        "K3 EDTA tube",
        "Serum tube (with and without separator gel)"
    ],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers",
        "Beckman Coulter (Olympus) AU400 Clinical Chemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme activity rate of change",
        "Spectrophotometry (410 nm)"
    ],
    "Methodologies": [
        "Enzyme kinetics using standard curve",
        "Quantitative enzyme activity assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for PLAC\u00ae Test for Lp-PLA2 Activity, an automated enzyme activity assay measuring Lp-PLA2 in EDTA-plasma and serum as a coronary heart disease risk aid",
    "Indications for Use Summary": "For in vitro quantitative determination of Lp-PLA2 activity in EDTA-plasma and serum on automated clinical chemistry analyzers, to aid in predicting risk of coronary heart disease in patients with no prior history of cardiovascular events; calibrators establish reference points and controls monitor assay performance",
    "fda_folder": "Immunology"
}